Summary
IINN Chart
Inspira Stock to Gain From its Appearance at Annual ELSO Conference
At the 34th annual ELSO conference in Detroit, IINN will present its FDA-cleared latest and future technology, the INSPIRA ART100 system.
IINN Stock Gains on Second US Patent Approval for VORTX System
Inspira secures a second U.S. Patent approval for the VORTX orbiting blood oxygenation delivery system.
Favorable Clinical Results for HYLA Sensor Might Boost Inspira Stock
IINN plans to report clinical results for its new HYLA blood sensor in open-heart surgery patients in the fourth quarter of 2024.
Inspira Technologies Oxy B.H.N. Ltd. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Anthony Scaramucci SkyBridge Capital II LLC | 4.14M | $1.85M | $1.85M | - | - |
 Jae Cho Marex Group plc | 11,061 | $4,940 | $4,940 | - | - |
 Matthew Riley Hickory Point Bank & Trust | 5,000 | $2,233 | $2,233 | - | - |
Inspira Technologies Oxy B.H.N. Ltd. (IINN) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Inspira Technologies Oxy B.H.N. Ltd. Profile
| Health Care Equipment & Supplies Industry | Healthcare Sector | Dagi Shahar Ben-Noon CEO | NASDAQ (CM) Exchange | M5S26K102 CUSIP |
| IL Country | 39 Employees | - Last Dividend | - Last Split | 14 Jul 2021 IPO Date |
Overview
Inspira Technologies Oxy B.H.N. Ltd., headquartered in Ra'annana, Israel, stands at the forefront of specialty medical device innovation, concentrating on the development and dissemination of advanced respiratory support technologies. Founded in 2018, the company was initially known as Insense Medical Ltd. before rebranding in July 2020 to its current title. Inspira Technologies is dedicated to offering groundbreaking solutions aimed at transforming the treatment landscape for patients suffering from acute respiratory failure. By focusing on the development, manufacture, and marketing of its proprietary systems, Inspira Technologies aims to furnish healthcare providers with viable alternatives to traditional invasive mechanical ventilation methods, marking a significant step forward in patient care and treatment efficacy.
Products and Services
Augmented Respiration Technology System: At the heart of Inspira Technologies’ offerings is its flagship product, the augmented respiration technology (ART) system. This innovative respiratory support system encompasses a minimally invasive, portable dual lumen cannula that is carefully inserted into the jugular vein of patients. The ART system stands out by employing extra-corporeal direct blood oxygenation technology. By directly oxygenating the blood outside the body, the system effectively elevates and stabilizes oxygen saturation levels in patients experiencing acute respiratory failures. This groundbreaking approach not only aims to improve patient outcomes but also seeks to reduce the need for, and the associated risks of, traditional invasive mechanical ventilation. Inspira Technologies’ commitment to fostering advancements in non-invasive respiratory support shines through this cutting-edge product, promising a new era of medical care for patients grappling with severe respiratory conditions.
